Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

KRIBB, France launch biotech-quantum alliance to cut drug development time

10 September 2026 · By · Wire by Fusion42

Published

10 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at mbiz.heraldcorp.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

KRIBB of South Korea has formed a partnership with French research institutes and a quantum computing company to jointly apply AI and quantum computing to biotechnology. Their goal is to accelerate drug development by reducing the typical time and cost needed to discover new drug candidates.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to integrate quantum computing and AI into your biotech pipeline now before competitors in South Korea and France seize the drug speed advantage. New collaborations like KRIBB and Quandela's signal this tech combo is moving from theory to practical use.

◆ Coverage

1 source · 10 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbiotechquantum-computingdrug-developmentinternational-partnershipAIsynthetic-biology